Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

June 14, 2023 0

Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the …

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

June 1, 2023 0

UT Southwestern Medical Center and RenovoRx RenovoRx Inc (RNXT) announced that the University of Texas (UT) …

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

May 30, 2023 0

Amylyx Pharmaceuticals Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization …

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

May 26, 2023 0

Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution …

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

May 19, 2023 0

Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization …

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

May 18, 2023 0

Prostate Cancer Prostate cancer is the most common type of cancer found in men, accounting for …

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI

May 15, 2023 0

Celldex Therapeutics Announcement Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with …

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

May 9, 2023 0

Longeveron in the NEWS On May 9, 2023, Longeveron (LGVN) announced new long-term follow-up data from …

Why CureVac Stock Traded Up in a Bad Day Market

May 8, 2023 0

CureVac B.V. CureVac (CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) …

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV

May 4, 2023 0

Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex® Today, May 4, 2023, Gilead Sciences (GILD) acknowledged …

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

May 1, 2023 0

May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

Our Eyes Are on Reata Pharmaceuticals Today

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

Why CureVac Stock Traded Up in a Bad Day Market

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

ImmunoGen’s Obvious Recent Progress

Vertex Receives CHMP Positive Opinion for ORKAMBI in Children with Cystic Fibrosis Aged 1 – >2 Years

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

Important News from Novartis MS Product Kesimpta®

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

Why the FDA Accepted to Review Merck’s KEYTRUDA (sBLA) for The Treatment of HER2 Negative Gastric Adenocarcinoma